Current status of data on cangrelor

Pharmacology and Therapeutics

Volumn 159, Issue , 2016, Pages 102-109

  Qamar, Arman ^a   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute coronary syndrome; Antiplatelet therapy; Cangrelor; Coronary artery disease; P2Y12 receptor inhibition; Percutaneous coronary intervention (PCI)

Indexed keywords

ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; HIRULOG; ADENOSINE PHOSPHATE; PURINERGIC P2Y RECEPTOR ANTAGONIST;

HUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENT THROMBOSIS; VASCULAR ACCESS; ANALOGS AND DERIVATIVES; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADENOSINE MONOPHOSPHATE; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84959454619     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.01.004     Document Type: Review

References (51)

1. K. Agrawal, and D.L. Bhatt Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI? Nat Rev Cardiol 10 2013 121 122
2. E.A. Amsterdam, N.K. Wenger, R.G. Brindis, D.E. Casey Jr., T.G. Ganiats, D.R. Holmes Jr., and et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines J Am Coll Cardiol 64 2014 139 228
3. D.J. Angiolillo, M.S. Firstenberg, M.J. Price, P.E. Tummala, M. Hutyra, I.J. Welsby, and et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial JAMA 307 2012 265 274
4. D.J. Angiolillo, D.J. Schneider, D.L. Bhatt, W.J. French, M.J. Price, J.F. Saucedo, and et al. Pharmacodynamic effects of cangrelor and clopidogrel: The platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials J Thromb Thrombolysis 34 2012 44 55
5. W.B. Batchelor, K.J. Anstrom, L.H. Muhlbaier, R. Grosswald, W.S. Weintraub, W.W. O'Neill, and et al. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: Results in 7,472 octogenarians. National Cardiovascular Network Collaboration J Am Coll Cardiol 36 2000 723 730
6. A. Bellemain-Appaix, S.A. O'Connor, J. Silvain, M. Cucherat, F. Beygui, O. Barthmy, and et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis JAMA 308 2012 2507 2516
7. D.L. Bhatt Tailoring antiplatelet therapy based on pharmacogenomics: How well do the data fit? JAMA 302 2009 896 897
8. D.L. Bhatt, J.S. Hulot, D.J. Moliterno, and R.A. Harrington Antiplatelet and anticoagulation therapy for acute coronary syndromes Circ Res 114 2014 1929 1943
9. D.L. Bhatt, A.M. Lincoff, C.M. Gibson, G.W. Stone, S. McNulty, G. Montalescot, and et al. Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
10. D.L. Bhatt, G.W. Stone, K.W. Mahaffey, C.M. Gibson, P.G. Steg, C.W. Hamm, and et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313
11. D.L. Bhatt, and E.J. Topol Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes JAMA 284 2000 1549 1558
12. M. Cavender, D.L. Bhatt, G. Stone, P. Steg, C.M. Gibson, C. Hamm, and et al. Cangrelor in elderly patients undergoing PCI: findings from CHAMPON PHOENIX J Am Coll Cardiol 65 2015 A1773
13. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, J. Silvain, and et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study Lancet 373 2009 309 317
14. H.L. Dauerman, D.L. Bhatt, D.D. Gretler, P.A. French, S.S. Smyth, and R.C. Becker Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients Am Heart J 159 2010 508 517
15. K.A. Fox, S.R. Mehta, R. Peters, F. Zhao, N. Lakkis, B.J. Gersh, and et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial Circulation 110 2004 1202 1208
16. F. Franchi, and D.J. Angiolillo Novel antiplatelet agents in acute coronary syndrome Nat Rev Cardiol 12 2015 30 47
17. A.B. Greenbaum, C.L. Grines, J.A. Bittl, R.C. Becker, D.J. Kereiakes, I.C. Gilchrist, and et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo-and active-controlled trial Am Heart J 151 2006 689.e1-689.e10
18. J.A. Gutierrez, R.A. Harrington, J.C. Blankenship, G.W. Stone, P.G. Steg, C.M. Gibson, and et al. The effect of cangrelor and access site on ischaemic and bleeding events: Insights from CHAMPION PHOENIX Eur Heart J 2015 10.1093/eurheartj/ehv498 (Epub ahead of print)
19. P. Greux, G.W. Stone, R.A. Harrington, C.M. Gibson, P.G. Steg, S.J. Brener, and et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: Insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention) J Am Coll Cardiol 63 2014 619 629
20. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, and et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
21. R.A. Harrington, G.W. Stone, S. McNulty, H.D. White, A.M. Lincoff, C.M. Gibson, and et al. Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
22. A.A. Heestermans, J.W. van Werkum, D. Taubert, T.H. Seesing, N. von Beckerath, C.M. Hackeng, and et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction Thromb Res 122 2008 776 781
23. P.M. Ho, E.D. Peterson, L. Wang, D.J. Magid, S.D. Fihn, G.C. Larsen, and et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome JAMA 299 2008 532 539
24. P.H. Huang, K.J. Croce, D.L. Bhatt, and F.S. Resnic Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation Crit Pathw Cardiol 11 2012 177 185
25. S. Leonardi, K.W. Mahaffey, H.D. White, C.M. Gibson, G.W. Stone, G.W. Steg, and et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial Am Heart J 163 2012 768 776
26. S. Leonardi, A.A. Truffa, M.L. Neely, P. Tricoci, H.D. White, C.M. Gibson, and et al. A novel approach to systematically implement the universal definition of myocardial infarction: Insights from the CHAMPION PLATFORM trial Heart 99 2013 1282 1287
27. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, J.T. Brandt, and et al. Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
28. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, M.K. Natarajan, and et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study Lancet 358 2001 527 555
29. M.L. O'Donoghue, D.L. Bhatt, G. Stone, P. Steg, C.M. Gibson, C. Hamm, and et al. The efficacy, safety, and net clinical benefit of cangrelor in women undergoing elective or urgent PCI: Insights from the CHAMPION PHOENIX trial Circulation 133 2016 248 255
30. P.T. O'Gara, F.G. Kushner, D.D. Ascheim, D.E. Casey Jr., M.K. Chung, J.A. de Lemos, and et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 78 140
31. R.V. Rao, S.G. Goodman, R.T. Yan, F.A. Spencer, K.A. Fox, J.P. DeYoung, and et al. Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes Am Heart J 157 2009 642 650
32. S.V. Rao, Z.G. Turi, S.C. Wong, S.J. Brener, and G.W. Stone Radial versus femoral access. (2013) J Am Coll Cardiol 62 2013 S11 S20
33. F. Rollini, F. Franchi, and D.J. Angiolillo Switching P2Y12-receptor inhibitors in patients with coronary artery disease Nat Rev Cardiol 13 2016 11 27
34. D.J. Schneider, Z. Agarwal, N. Seecheran, F.K. Keating, and P. Gogo Pharmacodynamic effects during the transition between cangrelor and ticagrelor JACC Cardiovasc Interv 7 2014 435 442
35. D.J. Schneider, N. Seecheran, S.S. Raza, F.K. Keating, and P. Gogo Pharmacodynamic effects during the transition between cangrelor and prasugrel Coron Artery Dis 26 2015 42 48
36. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, and et al. Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
37. L. Souckova, R. Opatrilova, P. Suk, I. Cundrle Jr., M. Pavlik, V. Zvonicek, and et al. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR) Eur J Clin Pharmacol 69 2013 309 317
38. P.G. Steg, D.L. Bhatt, C.W. Hamm, G.W. Stone, C.M. Gibson, K.W. Mahaffey, and et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data Lancet 382 2013 1981 1992
39. P.G. Steg, S.K. James, D. Atar, L.P. Badano, C. Blömstrom-Lundqvist, M.A. Borger, and et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) Eur Heart J 33 2012 2569 2619
40. S.R. Steinhubl, P.B. Berger, J.T. Mann, E.T. Fry, A. DeLago, C. Wilmer, and et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial JAMA 288 2002 2411 2420
41. R.F. Storey, K.G. Oldroyd, and R.G. Wilcox Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes Thromb Haemost 85 2001 401 407
42. R.F. Storey, H.M. Sanderson, A.E. White, J.A. May, K.E. Cameron, and S. Heptinsall The central role of the P(2 T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity Br J Haematol 110 2000 925 934
43. K. Thygesen, J.S. Alpert, A.S. Jaffe, M.L. Simoons, B.R. Chaitman, H.D. White, and et al. Third universal definition of myocardial infarction Circulation 126 2012 2020 2035
44. M. Valgimigli, A. Gagnor, P. Calabŕo, E. Frigoli, S. Leonardi, T. Zaro, and et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial Lancet 385 2015 2465 2476
45. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, J. Horrow, and et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
46. T.Y. Wang, D.J. Angiolillo, M. Cushman, M.S. Sabatine, P.F. Bray, S.S. Smyth, and et al. Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease J Am Coll Cardiol 59 2012 891 900
47. H.D. White, D.L. Bhatt, C.M. Gibson, C.W. Hamm, K.W. Mahaffey, M.J. Price, and et al. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: Insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]) JACC Cardiovasc Interv 8 2015 424 433
48. H.D. White, D.P. Chew, H.L. Dauerman, K.W. Mahaffey, C.M. Gibson, G.W. Stone, and et al. Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction Am Heart J 163 2012 182 190
49. P. Widimsky, Z. Motovska, S. Simek, P. Kala, R. Pudil, F. Holm, and et al. Clopidogrel pre-treatment in stable angina: For all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8 Eur Heart J 29 2008 1495 1503
50. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
51. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox, and et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502